Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05218018 · ClinicalTrials.gov registry record · NA

Triglyceride Effects on Blood Flow in the Human Brain

A NA study, sponsored by University of Washington.

Completed
Registry status
NA
Development phase
30
Enrollment target

NCT05218018 is a NA study that has completed, run by University of Washington. The registered enrollment target is 30 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05218018, a NA study, has completed, sponsored by University of Washington.

COMPLETED
Registry status
NA
Development phase
30 participants
Enrollment target

Study Summary

The 'Western diet' characterized by high fat feeding (HFF) is a risk factor for Alzheimer's disease (AD); however, little is known about mechanisms. Paradoxically, individuals who carry the AD risk gene APOE E4 cognitively improve after HFF and show different metabolic responses to fat intake. These responses include a more pronounced drop in systolic blood pressure and a decrease in cerebrospinal fluid glucose and lactate levels. This proposal will further examine the brain metabolic response to HFF using non-invasive imaging. Cerebral blood flow (CBF) as assessed by functional MRI is increasingly utilized to investigate brain function, given that CBF is tightly coupled to brain metabolism. Acute changes in CBF have been described in response to carbohydrate ingestion in regions important for learning and memory; however, no one has yet assessed CBF response to lipid. Here investigators propose to characterize CBF changes to a high fat drink in older adults. This study will include a time course assessment as well as analyses of global and regional change in CBF. These data would serve as feasibility pilot data for an R01 application which would include cognitive and peripheral metabolic data. These types of studies will provide a clearer picture of acute brain metabolic response to HFF in older adults, including the effects of APOE.

Interventions

  • DIETARY_SUPPLEMENT Lipid drink

Trial Details

FieldValue
Enrollment Target 30 participants
Start Date 2020-03-01
Est. Completion 2022-01-13
Phase NA

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT05218018

The ClinicalTrials.gov registry entry for NCT05218018 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Lipid drink is the first listed.

NCT05218018 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT05218018 about?

NCT05218018 is a clinical study titled "Triglyceride Effects on Blood Flow in the Human Brain". The 'Western diet' characterized by high fat feeding (HFF) is a risk factor for Alzheimer's disease (AD); however, little is known about mechanisms. Paradoxically, individuals who carry the AD risk gene APOE E4 cognitively improve after HFF and show different metabolic responses to fat intake. These...

What is the current status of trial NCT05218018?

This trial is currently completed. It is a NA study. The enrollment target is 30 participants. The study started on 2020-03-01. Estimated completion is 2022-01-13.

What interventions are being tested in trial NCT05218018?

The interventions under investigation include: Lipid drink (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT05218018?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.